CD8A and neoplasm: For example, efficacy of anthracyclines in breast cancer15–17 and oxaliplatin in colorectal cancer18 correlates with post-treatment increases in the ratio of cytotoxic CD8+ T lymphocytes to FoxP3+ regulatory T cells within the tumor.